---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-329513"
form_type: "8-K"
ticker: "INDV"
cik: "0001625297"
company_name: "Indivior Pharmaceuticals, Inc."
filed_at: "2026-08-03T10:40:42+00:00"
generated_at: "2026-08-03T10:45:08.552150+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Indivior to merge with Supernus in stock-for-stock deal; Indivior stockholders to own 56.5% of combined company

## Summary
- Exchange ratio: 1.5401 Indivior shares per Supernus share; Indivior stockholders own ~56.5%, Supernus ~43.5% on fully diluted basis.
- Indivior to pay $1B special dividend pre-closing, funded in part by $650M senior secured term loan from Citibank.
- Combined company renamed Supernus, Inc., trades on Nasdaq under 'SUPN'; Jack Khattar CEO, Timothy Dec CFO; board split 4-4.
- Termination fees: Indivior pays $174M if it walks for superior proposal; Supernus pays $101M; closing subject to stockholder and regulatory approvals.

## SEC filing metadata
- accession: 0001193125-26-329513
- form_type: 8-K
- ticker: INDV
- cik: 0001625297
- company_name: Indivior Pharmaceuticals, Inc.
- filed_at: 2026-08-03T10:40:42+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1625297/000119312526329513/0001193125-26-329513-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1625297/000119312526329513/d28447d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-329513
- JSON: https://secwatch.observer/filing/0001193125-26-329513.json
- Plain text: https://secwatch.observer/filing/0001193125-26-329513.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.